Analyst Upgrade: Wolfe Research recently lifted its rating on Biogen to Outperform from Peer Perform, setting a price target of $300 amid strength in the company's pipeline. Market participants on social media highlighted how this move reflects growing confidence in Biogen's strategic direction and upcoming developments. The upgrade has sparked conversations about potential momentum in the shares.
Acquisition News: Biogen's completion of the RayThera deal, valued at up to $1 billion, drew attention for adding immunology assets to its portfolio. Observers noted the acquisition's focus on an anti-inflammatory program entering Phase 1 trials as a key step in pipeline expansion. Discussions emphasized how such moves could position the firm for broader growth in immune-mediated conditions.
Note: This discussion summary was generated from an AI condensation of post data.
Biogen Insider Trading Activity
Biogen insiders have traded $BIIB stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $BIIB stock by insiders over the last 6 months:
- LLOYD MINOR has made 0 purchases and 2 sales selling 1,186 shares for an estimated $239,749.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Biogen Revenue
Biogen had revenues of $2.7B in Q2 2026. This is an increase of 3.42% from the same period in the prior year.
You can track BIIB financials on Quiver Quantitative's BIIB stock page.
You can access data on BIIB stock through the Quiver Quantitative API.
Biogen Congressional Stock Trading
Members of Congress have traded $BIIB stock 6 times in the past 6 months. Of those trades, 5 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $BIIB stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 06/05.
- REPRESENTATIVE MARIA ELVIRA SALAZAR has traded it 4 times. They made 3 purchases worth up to $130,000 on 05/12, 05/11 and 1 sale worth up to $50,000 on 06/02.
- SENATOR ALAN ARMSTRONG purchased up to $15,000 on 03/27.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
Biogen Hedge Fund Activity
We have seen 532 institutional investors add shares of Biogen stock to their portfolio, and 438 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 5,409,698 shares (+42.2%) to their portfolio in Q2 2026, for an estimated $1,168,819,349
- POINT72 ASSET MANAGEMENT, L.P. removed 2,003,575 shares (-71.2%) from their portfolio in Q1 2026, for an estimated $367,315,404
- JPMORGAN CHASE & CO added 1,823,140 shares (+inf%) to their portfolio in Q2 2026, for an estimated $393,907,628
- PACER ADVISORS, INC. added 1,122,981 shares (+inf%) to their portfolio in Q2 2026, for an estimated $242,631,274
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,117,663 shares (+inf%) to their portfolio in Q2 2026, for an estimated $241,482,267
- MILLENNIUM MANAGEMENT LLC removed 1,031,622 shares (-91.7%) from their portfolio in Q1 2026, for an estimated $189,127,261
- BARCLAYS PLC removed 753,533 shares (-57.7%) from their portfolio in Q1 2026, for an estimated $138,145,204
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Biogen Analyst Ratings
Wall Street analysts have issued reports on $BIIB in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 06/29/2026
- Evercore ISI Group issued a "Outperform" rating on 05/15/2026
- Guggenheim issued a "Buy" rating on 04/30/2026
To track analyst ratings and price targets for Biogen, check out Quiver Quantitative's $BIIB forecast page.
Biogen Price Targets
Multiple analysts have issued price targets for $BIIB recently. We have seen 16 analysts offer price targets for $BIIB in the last 6 months, with a median target of $225.0.
Here are some recent targets:
- Matthew Harrison from Morgan Stanley set a target price of $222.0 on 07/08/2026
- Brian Abrahams from RBC Capital set a target price of $242.0 on 07/07/2026
- Ami Fadia from Needham set a target price of $256.0 on 06/29/2026
- Salim Syed from Mizuho set a target price of $221.0 on 06/15/2026
- David Amsellem from Piper Sandler set a target price of $225.0 on 05/15/2026
- Geoff Meacham from Citigroup set a target price of $200.0 on 05/01/2026
- Yatin Suneja from Guggenheim set a target price of $260.0 on 04/30/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
